Cellectis (CLLS) Competitors $1.43 -0.03 (-2.05%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLLS vs. PHAT, RGNX, BNTC, ALLO, ORKA, TKNO, TRDA, MREO, HRTX, and CYRXShould you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Phathom Pharmaceuticals (PHAT), REGENXBIO (RGNX), Benitec Biopharma (BNTC), Allogene Therapeutics (ALLO), Oruka Therapeutics (ORKA), Alpha Teknova (TKNO), Entrada Therapeutics (TRDA), Mereo BioPharma Group (MREO), Heron Therapeutics (HRTX), and Cryoport (CYRX). These companies are all part of the "pharmaceutical products" industry. Cellectis vs. Phathom Pharmaceuticals REGENXBIO Benitec Biopharma Allogene Therapeutics Oruka Therapeutics Alpha Teknova Entrada Therapeutics Mereo BioPharma Group Heron Therapeutics Cryoport Phathom Pharmaceuticals (NASDAQ:PHAT) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, community ranking, valuation, institutional ownership and profitability. Do analysts rate PHAT or CLLS? Phathom Pharmaceuticals currently has a consensus target price of $22.17, indicating a potential upside of 424.03%. Cellectis has a consensus target price of $7.00, indicating a potential upside of 389.51%. Given Phathom Pharmaceuticals' higher possible upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Cellectis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Cellectis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, PHAT or CLLS? Phathom Pharmaceuticals has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.22, indicating that its share price is 222% more volatile than the S&P 500. Does the MarketBeat Community believe in PHAT or CLLS? Cellectis received 316 more outperform votes than Phathom Pharmaceuticals when rated by MarketBeat users. However, 72.93% of users gave Phathom Pharmaceuticals an outperform vote while only 65.14% of users gave Cellectis an outperform vote. CompanyUnderperformOutperformPhathom PharmaceuticalsOutperform Votes9772.93% Underperform Votes3627.07% CellectisOutperform Votes41365.14% Underperform Votes22134.86% Does the media refer more to PHAT or CLLS? In the previous week, Cellectis had 1 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 4 mentions for Cellectis and 3 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 0.97 beat Cellectis' score of 0.48 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectis 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in PHAT or CLLS? 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 24.1% of Phathom Pharmaceuticals shares are held by company insiders. Comparatively, 16.4% of Cellectis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is PHAT or CLLS more profitable? Cellectis has a net margin of -234.39% compared to Phathom Pharmaceuticals' net margin of -1,292.14%. Phathom Pharmaceuticals' return on equity of 0.00% beat Cellectis' return on equity.Company Net Margins Return on Equity Return on Assets Phathom Pharmaceuticals-1,292.14% N/A -79.57% Cellectis -234.39%-74.55%-22.65% Which has stronger valuation & earnings, PHAT or CLLS? Cellectis has lower revenue, but higher earnings than Phathom Pharmaceuticals. Cellectis is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhathom Pharmaceuticals$55.25M5.33-$201.59M-$5.35-0.79Cellectis$41.51M1.92-$101.06M-$0.83-1.72 SummaryPhathom Pharmaceuticals beats Cellectis on 11 of the 18 factors compared between the two stocks. Remove Ads Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLLS vs. The Competition Export to ExcelMetricCellectisBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$79.49M$2.84B$5.29B$7.36BDividend YieldN/A1.91%5.11%4.32%P/E Ratio-1.1030.3521.6917.68Price / Sales1.92433.43371.6292.88Price / CashN/A168.6838.1534.64Price / Book0.943.416.373.94Net Income-$101.06M-$72.06M$3.20B$247.45M7 Day Performance16.26%0.80%1.67%0.48%1 Month Performance15.32%-18.85%-9.49%-7.08%1 Year Performance-42.57%-30.49%9.59%-0.35% Cellectis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLLSCellectis2.7006 of 5 stars$1.43-2.1%$7.00+389.5%-44.3%$79.49M$41.51M-1.10290Short Interest ↑News CoverageGap DownPHATPhathom Pharmaceuticals3.7466 of 5 stars$4.63-5.1%$22.17+378.8%-52.4%$322.42M$55.25M-0.81110RGNXREGENXBIO4.7158 of 5 stars$6.33+7.5%$31.88+403.6%-63.7%$317.24M$83.33M-1.26370Positive NewsGap UpBNTCBenitec Biopharma2.1541 of 5 stars$13.27+5.1%$24.71+86.2%+178.6%$311.20M$80,000.00-8.7920Short Interest ↑Gap DownALLOAllogene Therapeutics2.9534 of 5 stars$1.43-1.4%$9.29+549.6%-58.9%$310.69M$22,000.00-0.92310ORKAOruka Therapeutics3.1168 of 5 stars$8.14+6.0%$39.86+389.6%N/A$304.77MN/A-1.30N/ANews CoveragePositive NewsGap UpTKNOAlpha Teknova1.7659 of 5 stars$5.67+1.4%$8.50+49.9%+129.5%$302.99M$37.75M-7.66240Positive NewsGap UpTRDAEntrada Therapeutics3.1079 of 5 stars$7.92+0.3%$25.67+224.1%-38.9%$297.75M$210.78M4.98110News CoveragePositive NewsMREOMereo BioPharma Group1.8434 of 5 stars$1.90-2.6%$7.71+306.0%-25.1%$294.78M$1M-31.6740HRTXHeron Therapeutics3.4984 of 5 stars$1.93+1.0%$5.67+193.6%-34.9%$294.00M$144.29M-10.72300Positive NewsCYRXCryoport2.6691 of 5 stars$5.66-1.9%$11.83+109.1%-67.0%$282.49M$228.39M-1.671,020Analyst ForecastGap Down Remove Ads Related Companies and Tools Related Companies PHAT Alternatives RGNX Alternatives BNTC Alternatives ALLO Alternatives ORKA Alternatives TKNO Alternatives TRDA Alternatives MREO Alternatives HRTX Alternatives CYRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLLS) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLLS Stock Free CLLS Stock Alerts